Catalio Capital Management, LP (Catalio), a multi-strategy life sciences investment firm, has today announced the launch of their Credit Opportunities strategy to expand the scope of the firm’s investments across the biomedical technology industry and meet the growing demand for non-dilutive growth capital within the sector.

The Catalio Credit Opportunities strategy seeks to provide senior-secured structured credit to breakthrough biomedical companies, targeting well-capitalized, pre-cashflow businesses with significant support from institutional investors. The strategy will be led by Co-Portfolio Managers John Henry Iucker and Robert Snyder. Mr. Iucker and Mr. Snyder both joined Catalio from Brown Advisory, an asset management firm with over $100B in AUM, where they played an instrumental role in building Brown’s credit platform.

In addition to Mr. Iucker and Mr. Snyder, Joshua Samuelson will be joining the Investment Committee of the Credit Opportunities strategy. Mr. Samuelson was a Co-Founder of PointState Capital, a long/short equity and macro-focused fund. At PointState, Mr. Samuelson served as President and managed a diverse portfolio across multiple asset classes until his retirement at the end of 2019. Prior to his time at PointState, he was a Portfolio Manager at Duquesne Capital Management and Soros Fund Management, where, over the course of his career, he focused on convertible bonds, equities and credit.

Catalio also announced today the appointment of Brandon Matz as the firm’s Head of Marketing & Investor Relations. Mr. Matz is joining Catalio from York Capital Management, a global alternative investment firm with approximately $20B in AUM.

The launch of the Catalio Credit Opportunities strategy is the latest milestone of many for Catalio, which has grown exponentially since its inception last year. It is now a leading multi-strategy investment firm, with over $450 million in committed capital between both private and public equity strategies.

George Petrocheilos and Dr. Jacob Vogelstein, Catalio’s Co-Founders & Co-Managing Partners said: “We are delighted to welcome John Henry, Rob, Josh and Brandon to Catalio. The life sciences industry continues to offer significant opportunities for investment, and these latest additions to our team will further augment our platform and help our transformative biomedical technology companies to bring their innovations to market.’’

Since inception, Catalio has invested in more than 20 prominent high-growth life science companies including AbCellera (NASDAQ: ABCL), COMPASS Pathways (NASDAQ: CMPS) and Thrive Earlier Detection (recently acquired by EXACT Sciences (NASDAQ: EXAS)). The firm closed its oversubscribed second venture fund, Catalio Nexus II, at its hard cap of $100 million in September 2020 and recently announced the launch of HealthCor Catalio Acquisition Corp. (NASDAQ: HCAQ), a special purpose acquisition company, targeting acquisitions in the healthcare industry.

About Catalio Capital Management L.P.

Catalio Capital Management, L.P., is a multi-strategy life sciences investment firm that focuses on breakthrough biomedical technology companies developing the next generation of drugs, devices, diagnostics and data-driven insights. Catalio’s General Partnership includes over 25 world-renowned scientists with extensive academic bona fides who have also started several successful companies based on their research. Catalio has offices in New York, Baltimore, and Washington, DC. For more information, visit www.cataliocapital.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005684/en/